{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:42:54Z","timestamp":1787002974594,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic cancer is an aggressive disease with low survival and high recurrence rates. A major obstacle in treating pancreatic cancer is the frequent development of chemoresistance to the standard therapeutic drug, gemcitabine. One mechanism by which pancreatic cancer develops chemoresistance is through the proliferation of cancer stem cells (CSC). However, the mechanisms regulating stemness in chemoresistant tumors remain unclear. Here, we found that the expression of the transcription factor Forkhead Box P1 (FOXP1) was elevated in chemoresistant pancreatic cancer and crucial for establishing CSC characteristics. Silencing FOXP1 reduced the expressions of stemness-associated genes and diminished the formation of both spheroids and colonies, highlighting the crucial role of FOXP1 in regulating stemness in chemoresistant tumor cells. Mechanistically, we discovered that FOXP1 regulates the expression of ATP-binding cassette superfamily G member 2 (ABCG2), which induces the efflux of gemcitabine. Knockdown of FOXP1 reduced the expression of ABCG2, resulting in decreased proliferation and increased sensitivity to gemcitabine. Moreover, the inhibition of FOXP1 in orthotopic mouse models reduced tumor growth and proliferation, and enhanced sensitivity to gemcitabine. Together, our data reveal FOXP1 as a potent oncogene that promotes CSC growth in chemoresistant pancreatic cancer.<\/jats:p>","DOI":"10.1038\/s41417-025-00896-7","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T15:17:16Z","timestamp":1743520636000},"page":"563-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The FOXP1-ABCG2 axis promotes the proliferation of cancer stem cells and induces chemoresistance in pancreatic cancer"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8139-4017","authenticated-orcid":false,"given":"Woosol Chris","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5081-2935","authenticated-orcid":false,"given":"Minsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Woong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-5567","authenticated-orcid":false,"given":"Sungsoon","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Sol","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooil","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-1247","authenticated-orcid":false,"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Seong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"896_CR1","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"896_CR2","doi-asserted-by":"crossref","unstructured":"Kim MJ, Kim HS, Kang HW, Lee DE, Hong WC, Kim JH, et al. SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancreatic cancer. Cells. 2023;12:2509.","DOI":"10.3390\/cells12202509"},{"key":"896_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.trsl.2022.11.007","volume":"255","author":"Z Tian","year":"2023","unstructured":"Tian Z, Tan Y, Lin X, Su M, Pan L, Lin L, et al. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1\/PI3K\/AKT\/mTOR axis. Transl Res. 2023;255:66\u201376.","journal-title":"Transl Res"},{"key":"896_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.117443","volume":"240","author":"M Ashrafizadeh","year":"2024","unstructured":"Ashrafizadeh M, Luo K, Zhang W, Reza Aref A, Zhang X. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug\/nanotherapeutic approaches. Environ Res. 2024;240:117443.","journal-title":"Environ Res"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.trecan.2022.08.005","volume":"8","author":"E Espinet","year":"2022","unstructured":"Espinet E, Klein L, Pur\u00e9 E, Singh SK. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer. 2022;8:1060\u201371.","journal-title":"Trends Cancer"},{"key":"896_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol"},{"key":"896_CR7","doi-asserted-by":"crossref","unstructured":"Hong WC, Lee DE, Kang HW, Kim MJ, Kim M, Kim JH, et al. CD74 promotes a pro-inflammatory tumor microenvironment by inducing S100A8 and S100A9 secretion in pancreatic cancer. Int J Mol Sci. 2023;24:12993.","DOI":"10.3390\/ijms241612993"},{"key":"896_CR8","doi-asserted-by":"crossref","unstructured":"Mercanti L, Sindaco M, Mazzone M, Di Marcantonio MC, Piscione M, Muraro R, et al. PDAC, the influencer cancer: cross-talk with tumor microenvironment and connected potential therapy strategies. Cancers. 2023;15:2923.","DOI":"10.3390\/cancers15112923"},{"key":"896_CR9","doi-asserted-by":"crossref","unstructured":"Galindo-Vega A, Maldonado-Lagunas V, Mitre-Aguilar IB, Melendez-Zajgla J. Tumor microenvironment role in pancreatic cancer stem cells. Cells. 2023;12:1560.","DOI":"10.3390\/cells12121560"},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00109-023-02369-6","volume":"101","author":"YS Lee","year":"2023","unstructured":"Lee YS, Kim HS, Kim HJ, Kang HW, Lee DE, Kim MJ, et al. The role of LOXL2 induced by glucose metabolism-activated NF-\u03baB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. J Mol Med. 2023;101:1449\u201364.","journal-title":"J Mol Med"},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2023.09.021","volume":"166","author":"Y Feng","year":"2024","unstructured":"Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, et al. BRD9-SMAD2\/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. Gastroenterology. 2024;166:139\u201354.","journal-title":"Gastroenterology"},{"key":"896_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256524","volume":"24","author":"Z Wu","year":"2023","unstructured":"Wu Z, Thierry K, Bachy S, Zhang X, Gamradt P, Hernandez-Vargas H, et al. Pericyte stem cells induce Ly6G(+) cell accumulation and immunotherapy resistance in pancreatic cancer. EMBO Rep. 2023;24:e56524.","journal-title":"EMBO Rep"},{"key":"896_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1053\/j.gastro.2021.03.051","volume":"161","author":"J Ai","year":"2021","unstructured":"Ai J, W\u00f6rmann SM, G\u00f6rg\u00fcl\u00fc K, Vallespinos M, Zagorac S, Alcala S, et al. Bcl3 couples cancer stem cell enrichment with pancreatic cancer molecular subtypes. Gastroenterology. 2021;161:318\u201332.e9.","journal-title":"Gastroenterology"},{"key":"896_CR14","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","volume":"11","author":"L Walcher","year":"2020","unstructured":"Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strau\u00df A, et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280.","journal-title":"Front Immunol"},{"key":"896_CR15","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1038\/s41388-021-01742-4","volume":"40","author":"H Li","year":"2021","unstructured":"Li H, Han X, Yang S, Wang Y, Dong Y, Tang T. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. Oncogene. 2021;40:2785\u2013802.","journal-title":"Oncogene"},{"key":"896_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13000-018-0715-y","volume":"13","author":"BH Yu","year":"2018","unstructured":"Yu BH, Li BZ, Zhou XY, Shi DR, Yang WT. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer. Diagn Pathol. 2018;13:36.","journal-title":"Diagn Pathol"},{"key":"896_CR17","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.18632\/oncotarget.6510","volume":"7","author":"EJ Choi","year":"2016","unstructured":"Choi EJ, Seo EJ, Kim DK, Lee SI, Kwon YW, Jang IH, et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget. 2016;7:3506\u201319.","journal-title":"Oncotarget"},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"e0280794","DOI":"10.1371\/journal.pone.0280794","volume":"18","author":"L Wang","year":"2023","unstructured":"Wang L, Luo P, Yang Z, Zhong X, Ji C. FOXP1 inhibits pancreatic cancer growth by transcriptionally regulating IRF1 expression. PLoS ONE. 2023;18:e0280794.","journal-title":"PLoS ONE"},{"key":"896_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3892\/ol.2021.13055","volume":"22","author":"J Zhao","year":"2021","unstructured":"Zhao J, Wu F, Yang J. A novel long non-coding RNA TTN-AS1\/microRNA-589-5p\/FOXP1 positive feedback loop increases the proliferation, migration and invasion of pancreatic cancer cell lines. Oncol Lett. 2021;22:794.","journal-title":"Oncol Lett"},{"key":"896_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.934746","volume":"13","author":"DE Lee","year":"2022","unstructured":"Lee DE, Kang HW, Kim SY, Kim MJ, Jeong JW, Hong WC, et al. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Front Pharmacol. 2022;13:934746.","journal-title":"Front Pharmacol"},{"key":"896_CR21","first-page":"2617","volume":"16","author":"SJ Chen","year":"2024","unstructured":"Chen SJ, Ren LK, Fei XB, Liu P, Wang X, Zhu CH, et al. A study on the role of Taxifolin in inducing apoptosis of pancreatic cancer cells: screening results using weighted gene co-expression network analysis. Aging. 2024;16:2617\u201337.","journal-title":"Aging"},{"key":"896_CR22","doi-asserted-by":"publisher","first-page":"e31507","DOI":"10.1371\/journal.pone.0031507","volume":"7","author":"G Zhang","year":"2012","unstructured":"Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS ONE. 2012;7:e31507.","journal-title":"PLoS ONE"},{"key":"896_CR23","doi-asserted-by":"crossref","unstructured":"Ono H, Murase Y, Yamashita H, Kato T, Asano D, Ishikawa Y, et al. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Int J Oncol. 2023;62:51.","DOI":"10.3892\/ijo.2023.5499"},{"key":"896_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110909","volume":"133","author":"G Babaei","year":"2021","unstructured":"Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; the three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.","journal-title":"Biomed Pharmacother"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-16-3143","volume":"77","author":"X Jin","year":"2017","unstructured":"Jin X, Pan Y, Wang L, Ma T, Zhang L, Tang AH, et al. Fructose-1,6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK interaction. Cancer Res. 2017;77:4328\u201341.","journal-title":"Cancer Res"},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","volume":"41","author":"L de Wet","year":"2022","unstructured":"de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022;41:1190\u2013202.","journal-title":"Oncogene"},{"key":"896_CR27","doi-asserted-by":"crossref","unstructured":"Mamouni K, Kim J, Lokeshwar BL, Kallifatidis G. ARRB1 regulates metabolic reprogramming to promote glycolysis in stem cell-like bladder cancer cells. Cancers. 2021;13:1809.","DOI":"10.3390\/cancers13081809"},{"key":"896_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4161\/15384101.2014.974419","volume":"14","author":"YA Shen","year":"2015","unstructured":"Shen YA, Wang CY, Hsieh YT, Chen YJ, Wei YH. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle. 2015;14:86\u201398.","journal-title":"Cell Cycle"},{"key":"896_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41388-020-01518-2","volume":"40","author":"RK Nimmakayala","year":"2021","unstructured":"Nimmakayala RK, Leon F, Rachagani S, Rauth S, Nallasamy P, Marimuthu S, et al. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Oncogene. 2021;40:215\u201331.","journal-title":"Oncogene"},{"key":"896_CR30","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11033-021-06155-w","volume":"48","author":"PM Juan-Carlos","year":"2021","unstructured":"Juan-Carlos PM, Perla-Lidia PP, Stephanie-Talia MM, M\u00f3nica-Griselda AM, Luz-Mar\u00eda TE. ABC transporter superfamily. an updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine. Mol Biol Rep. 2021;48:1883\u2013901.","journal-title":"Mol Biol Rep"},{"key":"896_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.53","volume":"8","author":"Y Hou","year":"2017","unstructured":"Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B, et al. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 2017;8:e2659.","journal-title":"Cell Death Dis"},{"key":"896_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115666","volume":"259","author":"J Zhu","year":"2023","unstructured":"Zhu J, Lei S, Lu J, Hao Y, Qian Q, Devanathan AS, et al. Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors. Eur J Med Chem. 2023;259:115666.","journal-title":"Eur J Med Chem"},{"key":"896_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jphotobiol.2017.10.035","volume":"178","author":"SA Abdel Gaber","year":"2018","unstructured":"Abdel Gaber SA, M\u00fcller P, Zimmermann W, H\u00fcttenberger D, Wittig R, Abdel Kader MH, et al. ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143. J Photochem Photobiol B. 2018;178:182\u201391.","journal-title":"J Photochem Photobiol B"},{"key":"896_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1158\/1541-7786.MCR-16-0270-T","volume":"15","author":"NG Sabnis","year":"2017","unstructured":"Sabnis NG, Miller A, Titus MA, Huss WJ. The efflux transporter ABCG2 maintains prostate stem cells. Mol Cancer Res. 2017;15:128\u201340.","journal-title":"Mol Cancer Res"},{"key":"896_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.","journal-title":"Signal Transduct Target Ther"},{"key":"896_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102449","volume":"89","author":"ASM Mahadiuzzaman","year":"2024","unstructured":"Mahadiuzzaman ASM, Dain Md Opo FA, Alkarim S. Stem cell-based targeted therapy in pancreatic cancer: current approaches and future prospects. Tissue Cell. 2024;89:102449.","journal-title":"Tissue Cell"},{"key":"896_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.18632\/aging.204455","volume":"15","author":"W Hu","year":"2023","unstructured":"Hu W, Li M, Wang Y, Zhong C, Si X, Shi X, et al. Comprehensive bioinformatics analysis reveals the significance of forkhead box family members in pancreatic adenocarcinoma. Aging. 2023;15:92\u2013107.","journal-title":"Aging"},{"key":"896_CR38","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1210\/me.2014-1171","volume":"28","author":"K Takayama","year":"2014","unstructured":"Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Takahashi S, Homma Y, et al. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol. 2014;28:2012\u201324.","journal-title":"Mol Endocrinol"},{"key":"896_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11882-x","volume":"24","author":"C Tang","year":"2024","unstructured":"Tang C, Zhuang H, Tong H, Yu X, Chen J, Wang Q, et al. Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma. BMC Cancer. 2024;24:137.","journal-title":"BMC Cancer"},{"key":"896_CR40","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41563-024-01908-x","volume":"23","author":"BL LeSavage","year":"2024","unstructured":"LeSavage BL, Zhang D, Huerta-L\u00f3pez C, Gilchrist AE, Krajina BA, Karlsson K, et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat Mater. 2024;23:1138\u201349.","journal-title":"Nat Mater"},{"key":"896_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.devcel.2018.10.001","volume":"47","author":"NY Fu","year":"2018","unstructured":"Fu NY, Pal B, Chen Y, Jackling FC, Milevskiy M, Vaillant F, et al. Foxp1 is indispensable for ductal morphogenesis and controls the exit of mammary stem cells from quiescence. Dev Cell. 2018;47:629\u201344.e8.","journal-title":"Dev Cell"},{"key":"896_CR42","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1111\/jcmm.13837","volume":"22","author":"X Sun","year":"2018","unstructured":"Sun X, Wang J, Huang M, Chen T, Chen J, Zhang F, et al. STAT3 promotes tumour progression in glioma by inducing FOXP1 transcription. J Cell Mol Med. 2018;22:5629\u201338.","journal-title":"J Cell Mol Med"},{"key":"896_CR43","doi-asserted-by":"crossref","unstructured":"Pelosi E, Castelli G, Testa U. Pancreatic cancer: molecular characterization, clonal evolution and cancer stem cells. Biomedicines. 2017;5:65.","DOI":"10.3390\/biomedicines5040065"},{"key":"896_CR44","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.7150\/thno.41648","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721\u201343.","journal-title":"Theranostics"},{"key":"896_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0600-4","volume":"16","author":"PR Prasetyanti","year":"2017","unstructured":"Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16:41.","journal-title":"Mol Cancer"},{"key":"896_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.723798","volume":"12","author":"A Chisari","year":"2021","unstructured":"Chisari A, Gol\u00e1n I, Campisano S, G\u00e9labert C, Moustakas A, Sancho P, et al. Glucose and amino acid metabolic dependencies linked to stemness and metastasis in different aggressive cancer types. Front Pharmacol. 2021;12:723798.","journal-title":"Front Pharmacol"},{"key":"896_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61516-2","volume":"14","author":"VM Perelmuter","year":"2024","unstructured":"Perelmuter VM, Grigoryeva ES, Savelieva OE, Alifanov VV, Andruhova ES, Zavyalova MV, et al. EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients. Sci Rep. 2024;14:12245.","journal-title":"Sci Rep"},{"key":"896_CR48","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.devcel.2018.05.027","volume":"45","author":"NM Aiello","year":"2018","unstructured":"Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, et al. EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell. 2018;45:681\u201395.e4.","journal-title":"Dev Cell"},{"key":"896_CR49","doi-asserted-by":"crossref","unstructured":"Sinha D, Saha P, Samanta A, Bishayee A. Emerging concepts of hybrid epithelial-to-mesenchymal transition in cancer progression. Biomolecules. 2020;10:1561.","DOI":"10.3390\/biom10111561"},{"key":"896_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","volume":"6","author":"LE Navas","year":"2021","unstructured":"Navas LE, Carnero A. NAD(+) metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6:2.","journal-title":"Signal Transduct Target Ther"},{"key":"896_CR51","doi-asserted-by":"publisher","first-page":"102082","DOI":"10.1016\/j.tranon.2024.102082","volume":"49","author":"Z Yu","year":"2024","unstructured":"Yu Z, Sun J, Fang K, Xu J, Yang J, Chunlei D, et al. SLC2A1 boosts the resistance of non-small cell lung cancer to taxanes by stimulating the formation of EPCAM(+) cancer stem-like cells via glycolysis. Transl Oncol. 2024;49:102082.","journal-title":"Transl Oncol"},{"key":"896_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101461","volume":"5","author":"B Ku","year":"2024","unstructured":"Ku B, Eisenbarth D, Baek S, Jeong TK, Kang JG, Hwang D, et al. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Cell Rep Med. 2024;5:101461.","journal-title":"Cell Rep Med"},{"key":"896_CR53","doi-asserted-by":"publisher","first-page":"101953","DOI":"10.1016\/j.redox.2021.101953","volume":"44","author":"K Tuy","year":"2021","unstructured":"Tuy K, Rickenbacker L, Hjelmeland AB. Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance. Redox Biol. 2021;44:101953.","journal-title":"Redox Biol"},{"key":"896_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109521","volume":"121","author":"S Dai","year":"2020","unstructured":"Dai S, Peng Y, Zhu Y, Xu D, Zhu F, Xu W, et al. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Biomed Pharmacother. 2020;121:109521.","journal-title":"Biomed Pharmacother"},{"key":"896_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2024.130669","volume":"1868","author":"S Pang","year":"2024","unstructured":"Pang S, Shen Y, Wang Y, Chu X, Ma L, Zhou Y. ROCK1 regulates glycolysis in pancreatic cancer via the c-MYC\/PFKFB3 pathway. Biochim Biophys Acta Gen Subj. 2024;1868:130669.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"896_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh1891","volume":"9","author":"J Cui","year":"2023","unstructured":"Cui J, Christin JR, Reisz JA, Cendali FI, Sanawar R, Coutinho De Miranda M, et al. Targeting ABCA12-controlled ceramide homeostasis inhibits breast cancer stem cell function and chemoresistance. Sci Adv. 2023;9:eadh1891.","journal-title":"Sci Adv"},{"key":"896_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apsb.2020.09.016","volume":"11","author":"H Duan","year":"2021","unstructured":"Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11:55\u201370.","journal-title":"Acta Pharm Sin B"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00896-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00896-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00896-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T18:03:13Z","timestamp":1747591393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00896-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00896-7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Our research complied with the ethical guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Gangnam Severance Hospital (no.3-2021-0414). Biospecimens (tissues) were collected from patients diagnosed with PDAC and those with normal pancreas undergoing surgical resection or tissue biopsy at the Gangnam Severance Hospital. We obtained written informed consent from all participants before including them in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}